Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Total Current Liabilities (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Total Current Liabilities for 10 consecutive years, with $13.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 72.2% year-over-year to $13.6 million, compared with a TTM value of $13.6 million through Sep 2025, down 72.2%, and an annual FY2024 reading of $49.1 million, up 32.09% over the prior year.
  • Total Current Liabilities was $13.6 million for Q3 2025 at Spero Therapeutics, down from $14.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $69.2 million in Q1 2022 and bottomed at $12.8 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $28.1 million, with a median of $21.6 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities soared 289.57% in 2022, then tumbled 72.2% in 2025.
  • Year by year, Total Current Liabilities stood at $18.7 million in 2021, then increased by 15.96% to $21.6 million in 2022, then surged by 71.62% to $37.2 million in 2023, then skyrocketed by 32.09% to $49.1 million in 2024, then tumbled by 72.19% to $13.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for SPRO at $13.6 million in Q3 2025, $14.9 million in Q2 2025, and $29.2 million in Q1 2025.